Search results for "prostate-specific antigen"

showing 10 items of 75 documents

Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study

2017

Background The vast majority of prostate cancer presents clinically localized to the prostate without evidence of metastasis. Currently, there are several modalities available to treat this particular disease. Despite radical prostatectomy demonstrating a modest prostate cancer specific mortality benefit in the PIVOT trial, several novel modalities have emerged to treat localized prostate cancer in patients that are either not eligible for surgery or that prefer an alternative approach. Methods Athymic nude mice were subcutaneously inoculated with prostate cancer cells. The mice were divided into four cohorts, one cohort untreated, two cohorts received docetaxel (10 mg/kg) either subcutaneo…

MaleOncologymedicine.medical_specialtyUrologymedicine.medical_treatmentMice NudeAntineoplastic AgentsDocetaxel02 engineering and technologyMetastasisMice03 medical and health sciencesProstate cancerDrug Delivery Systems0302 clinical medicineProstateIn vivoInternal medicinemedicineAnimalsMinimally Invasive Surgical ProceduresProstatectomybusiness.industryProstatectomyProstatic NeoplasmsProstate-Specific Antigen021001 nanoscience & nanotechnologymedicine.diseaseTumor BurdenSurgeryTreatment Outcomemedicine.anatomical_structureOncologyDocetaxel030220 oncology & carcinogenesisCohortMagnetsImmunohistochemistryTaxoidsDrug Monitoring0210 nano-technologybusinessmedicine.drugThe Prostate
researchProduct

Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Fe…

2017

The aim of this study was to evaluate the acute toxicity profiles of a moderate hypofractionated regimen with volumetric modulated arc therapy (VMAT) in patients with prostate cancer (PC) who underwent radical prostatectomy.From December 2012 to February 2016, 125 patients, previously having undergone radical prostatectomy, received adjuvant (64 patients) or salvage (61 patients) radiotherapy (RT) inside an institutional protocol of moderate hypofractionation schedule using the VMAT technique (Varian RapidArc, Palo Alto, CA). Eligible patients were 85 years old, with an Eastern Cooperative Oncology Group performance status of 0 to 2, histologically proven adenocarcinoma of the prostate with…

MaleOncologymedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyUrinary incontinenceDisease-Free Survival030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancersymbols.namesake0302 clinical medicineInternal medicinemedicineHumansAdjuvantFisher's exact testAgedNeoplasm StagingAged 80 and overProstatectomySalvage TherapyProstate cancerRadiotherapyAdjuvant; Hypofractionation; Prostate cancer; Radiotherapy; Salvage; Oncology; Urologybusiness.industryProstatectomyProstatic NeoplasmsCommon Terminology Criteria for Adverse EventsMiddle AgedProstate-Specific Antigenmedicine.diseaseAcute toxicityRadiation therapyRegimenTreatment OutcomeOncology030220 oncology & carcinogenesissymbolsHypofractionationSalvageRadiation Dose HypofractionationRadiotherapy AdjuvantRadiotherapy Intensity-Modulatedmedicine.symptombusinessRadiotherapy Image-GuidedClinical Genitourinary Cancer
researchProduct

Multiple Estrogen Function in Human Prostate Cancer Cells

1996

MalePCA3Oncologymedicine.medical_specialtyNeoplasms Hormone-DependentCell divisionmedicine.drug_classGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceHeat shock proteinInternal medicineTumor Cells CulturedAnimalsHumansMedicineHeat-Shock Proteinsbusiness.industryCadherinGeneral NeuroscienceProstatic NeoplasmsCancerEstrogensProstate-Specific AntigenCadherinsmedicine.diseaseRatsProstate-specific antigenReceptors EstrogenEstrogenCancer cellAndrogensbusinessCell DivisionAnnals of the New York Academy of Sciences
researchProduct

Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis.

2022

Abstract Objectives Prostate cancer (PCa) represents the second most common solid cancer in men worldwide. In the last decades, the prostate health index (PHI) emerged as a reliable biomarker for detecting PCa and differentiating between non-aggressive and aggressive forms. However, before introducing it in clinical practice, more evidence is required. Thus, we performed a systematic review and meta-analysis for assessing the diagnostic performance of PHI for PCa and for detecting clinically significant PCa (csPCa). Methods Relevant publications were identified by a systematic literature search on PubMed and Web of Science from inception to January 11, 2022. Results Sixty studies, including…

MalePCaprostate tumordiagnosisscreeningBiopsyBiochemistry (medical)Clinical BiochemistryProstateProstatic NeoplasmsGeneral MedicineProstate-Specific AntigenSettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinicaclinically significant prostate cancer (csPCa)biomarkerHumansprostate health index (PHI)BiomarkersClinical chemistry and laboratory medicineReferences
researchProduct

Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.

2015

Abstract Background Artemisia annua L, artemisinin and artesunate reveal profound activity not only against malaria, but also against cancer in vivo and clinical trials. Longitudinal observations on the efficacy of A. annua in patients are, however missing as of yet. Methods Clinical diagnosis was performed by imaging techniques (MRT, scintigraphy, SPECT/CT) and blood examinations of standard parameters from clinical chemistry. Immunohistochemistry of formalin-fixed, paraffin-embedded tumor material was performed to determine the expression of several biomarkers (cycloxygenase-2 (COX2), epidermal growth factor receptor (EGFR), glutathione S-transferase P1 (GSTP1), Ki-67, MYC, oxidized low d…

MalePathologymedicine.medical_specialtyArtemisia annuaPharmaceutical ScienceArtesunateBone NeoplasmsArtemisia annuaScintigraphyProstate cancerCell Line TumorDrug DiscoveryBiopsymedicineBiomarkers TumorHumansNeoplasm MetastasisTumor markerPharmacologyAged 80 and overbiologymedicine.diagnostic_testCancerProstatic NeoplasmsProstate-Specific Antigenbiology.organism_classificationmedicine.diseaseImmunohistochemistryArtemisininsProstate-specific antigenComplementary and alternative medicineVascular endothelial growth factor CDrug Resistance NeoplasmCancer researchMolecular MedicinePhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific …

1997

Abstract Objectives To investigate the clinical value of human glandular kallikrein (hK2) reverse transcriptase-polymerase chain reaction (RT-PCR) for detection of prostate cells in circulation and to compare the results with those obtained from prostate-specific antigen (PSA) RT-PCR. Methods We examined peripheral blood (PB) and bone marrow (BM) samples of 13 patients with advanced-stage prostate cancer and 63 patients with clinically localized disease for the presence of circulating prostate cells. An RT-PCR protocol with a two-step amplification cycle and hot-start conditions was used. Results The limit of detection of the PCR portion is similar for PSA and hK2 (5 to 10 copies of the pla…

MalePathologymedicine.medical_specialtyUrologyurologic and male genital diseasesPolymerase Chain ReactionPeripheral blood mononuclear cellProstate cancerAntigenProstateLNCaPHumansMedicineRNA MessengerHuman Glandular Kallikreinbusiness.industryProstatic NeoplasmsProstate-Specific AntigenNeoplastic Cells Circulatingmedicine.diseaseMolecular biologyProstate-specific antigenmedicine.anatomical_structureKallikreinsBone marrowbusinessTissue KallikreinsUrology
researchProduct

Relative advantages and disadvantages of radical perineal prostatectomy versus radical retropubic prostatectomy

2002

In recent years prostate cancer has become the predominant malignancy in men. With the introduction of prostate specific antigen (PSA) the disease can be diagnosed at an early stage, at which surgical therapy can be curative. In the past century, the retropubic and the perineal routes were established as alternatives of surgical access to the gland for clinically localized prostate cancer. The selection of the operative route is mostly decided individually on the basis of surgical training and experience. The revived interest in perineal radical prostatectomy is explained by the fact that this technique has been associated with low morbidity. The differences of both surgical approaches of r…

MaleProstatectomymedicine.medical_specialtyProstatectomybusiness.industryContraindicationsmedicine.medical_treatmentProstatic NeoplasmsHematologyPerineumMalignancymedicine.diseasePerineumSurgeryProstate-specific antigenProstate cancerPostoperative Complicationsmedicine.anatomical_structureOncologyProstatemedicineHumansbusinessRadical perineal prostatectomyRadical retropubic prostatectomyCritical Reviews in Oncology/Hematology
researchProduct

Relationship between PTH and PSA Values in Patients with Pathological Finding of Benign Prostatic Hyperplasia

2012

The functional relationship between parathyroid glands and prostatic gland is commonly very well known. The aim of our study was to investigate the relationship between serum levels of PTH and serum levels of PSA in patients with pathological finding of BPH. According to 261 transrectal ultrasound-guided prostatic biopsies performed from March 2009 to March 2010, 75 patients, responding to our inclusion criteria, were selected. 26 patients (34.6%) ended the study. All patients with high serum levels of PSA (>4 ng/mL), with histological diagnosis of benign prostatic hyperplasia, underwent the assay of serum levels of PTH. We observed high levels of PTH (> 66 pg/mL) in 9 patients (35.2…

MaleProstatic GlandAgingmedicine.medical_specialtyBiopsyProstatic HyperplasiaUrologyProstatic biopsyHistological diagnosisBiopsymedicineHumansIn patientPathologicalAgedCalcifediolAged 80 and overmedicine.diagnostic_testbusiness.industryHigh serumProstateGeneral MedicineMiddle AgedProstate-Specific AntigenHyperplasiamedicine.diseaseParathyroid HormonebusinessUrologia Journal
researchProduct

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?

2014

Even in the current era of dose-escalated radiotherapy for prostate cancer, biochemical recurrence is not uncommon. Furthermore, biochemical failure is not specific to the site of recurrence. One of the major challenges in the management of prostate cancer patients with biochemical failure after radiotherapy is the early discrimination between those with locoregional recurrence only and those with metastatic disease. While the latter are generally considered incurable, patients with locoregional disease may benefit from emerging treatment options. Ultimately, the objective of salvage therapy is to control disease while ensuring minimal collateral damage, thereby optimizing both cancer and t…

MaleQuality ControlOncologyBiochemical recurrencemedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBrachytherapyBrachytherapySalvage therapyBone Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineAdenocarcinomaRadiosurgeryMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineManagement of prostate cancerProstate cancerInternal medicinemedicineHumansMulticenter Studies as TopicRadiology Nuclear Medicine and imagingComputingMilieux_MISCELLANEOUSProstatectomySalvage TherapyLymphatic Irradiationbusiness.industryPalliative CareProstatic NeoplasmsCancerAndrogen AntagonistsRadiotherapy DosageProstate-Specific Antigenmedicine.diseaseCombined Modality Therapy3. Good healthRadiation therapyProstate-specific antigenOncologyLymphatic MetastasisDose Fractionation RadiationRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessRadiotherapy Image-Guided
researchProduct

Perineal complications following radical perineal prostatectomy.

2003

PURPOSE Radical perineal prostatectomy has recently attracted renewed interest and wider acceptance as an alternative route to the retropubic approach. While presumed lower morbidity is one reason for perineal prostatectomy we evaluated our patients for complications that are specific for the perineal approach. PATIENTS AND METHODS We have retrospectively analyzed 412 patients who underwent perineal prostatectomy from 10/1996 to 12/2000. Patients for the perineal approach were selected on the base of preoperative PSA (10 ng/ml) and biopsy Gleason score (< 7) without the need for simultaneous lymphadenectomy. A cystogram was performed routinely on day 7 p. o. and the catheter removed when pa…

MaleReoperationmedicine.medical_specialtyTime FactorsUrologymedicine.medical_treatmentFistulaBiopsyAnastomosisPerineumHematomaPostoperative ComplicationsmedicineHumansIntraoperative ComplicationsRetrospective StudiesProstatectomybusiness.industryUrinary retentionColostomyProstateProstatic NeoplasmsPerioperativeProstate-Specific Antigenmedicine.diseaseSurgeryCathetermedicine.symptombusinessRadical perineal prostatectomyAktuelle Urologie
researchProduct